Jump to Header Jump to Main Content Jump to Footer

Developing a Trial-Ready Cohort of Parkinson Disease Patients

Nicolas Phielipp

A Study On:

  • Parkinson Disease


  • Open

Official Title

Developing a Trial-Ready Cohort of Parkinson Disease Patients


You can join if...

Inclusion Criteria:

  • Adults 50-70 years of age (inclusive) who are able and willing to provide informed consent
  • Diagnosed with Parkinson Disease
  • At least 3 of the following clinical features: rigidity, bradykinesia, postural reflex impairment and
    resting tremor
  • At least one of the above must be rigidity or bradykinesia
  • The above clinical features must not be due to trauma, brain tumor, infection, cerebrovascular
    disease, other known neurological disease (e.g., multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome, striatonigral degeneration, Huntington's disease,
    Wilson's disease, or to known drugs, chemicals or toxicants)
  • At least 4 years since clinical diagnosis of Parkinson Disease
  • Modified Hoehn and Yahr Stage 2.5 - 4 off medication by history
  • Unequivocal motor response to levodopa by history
  • Participant reports at least 2 hours of "off"; time daily by history

Exclusion Criteria:

  • Prior brain surgery
  • History of cognitive impairment or dementia
  • Severe dyskinesia by history
  • History of stroke or poorly controlled cardiovascular disease
  • History of coagulopathy or inability to temporarily stop anticoagulation or antiplatelet therapy for at least 2 weeks
  • History of malignancy (cerebral or systemic) other than treated cutaneous squamous or basal cell carcinomas within the prior 5 years
  • Uncontrolled hypertension or diabetes or any other acute or chronic medical condition that would significantly increase the risks of a neurosurgical procedure
  • Chronically active infection by history or serological testing, including acute or chronic scalp infection
  • Presence or history of psychosis, including if induced by anti-Parkinson Disease medications at doses required to improve motor symptoms
  • Contraindication to MRI and/or use of gadolinium
  • Pregnancy or lactation
  • Chronic immunosuppressive therapy (e.g. chronic steroids, tumor necrosis factor (TNF) antagonists, chemotherapy)
  • Received investigational agent within 12 weeks prior to screening
  • Presence of substance (drug, alcohol) abuse
  • The presence of prominent oculomotor palsy, cerebellar signs, vocal cord paresis, or orthostatic hypotension (>20 mm Hg drop in systolic pressure or > 10 mm Hg in diastolic pressure, pyramidal tract signs or amyotrophy)
  • Presence of dementia (Montreal Cognitive Assessment (MoCA) < 26)
  • Positive blood test for antibodies to human immunodeficiency virus (HIV) types 1 or 2, hepatitis B virus (HBV) core antigen, hepatitis C virus (HCV), Treponema pallidum (syphilis), or West-Nile virus

Get in touch with our study team